INmune Bio Inc (INMB) — Cash Flow-to-Debt Ratio
INmune Bio Inc (INMB) has a Cash Flow-to-Debt Ratio of -0.68x as of September 2025, meaning its operating cash flow of $-5.44 Million could theoretically repay -1% of its total liabilities ($7.98 Million) in one year. See INMB working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
INmune Bio Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for INmune Bio Inc across 10 annual periods. Also explore INMB year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for INmune Bio Inc (2015–2024)
Year-by-year debt coverage analysis for INmune Bio Inc. For market capitalisation and broader financial context, see INMB stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -4.47x | $-33.36 Million | $7.46 Million | ▼ -603.6% |
| 2023 | -0.64x | $-11.98 Million | $18.86 Million | ▲ +39.3% |
| 2022 | -1.05x | $-22.69 Million | $21.69 Million | ▲ +27.6% |
| 2021 | -1.45x | $-28.50 Million | $19.72 Million | ▲ +69.3% |
| 2020 | -4.70x | $-8.94 Million | $1.90 Million | ▲ +24.9% |
| 2019 | -6.26x | $-5.38 Million | $860.54K | ▼ -150.3% |
| 2018 | -2.50x | $-2.06 Million | $823.77K | ▼ -1.6% |
| 2017 | -2.46x | $-761.83K | $309.72K | ▼ -365.6% |
| 2016 | -0.53x | $-317.38K | $600.81K | ▲ +10.3% |
| 2015 | -0.59x | $-18.12K | $30.75K | — |